

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1-18. (Cancelled)

19. (Currently Amended) A method for treating lymphoma ~~or leukemia~~ in a mammal comprising administering to the mammal a therapeutically effective amount of a variant of a parent antibody which binds CD20 and comprises an Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively than the parent antibody and comprises at least one amino acid substitution ~~modification~~ in the Fc region, wherein the Fc region of the variant is not a native sequence Fc region.

20. (Currently Amended) The method of claim 21 wherein the variant comprises a variant human IgG1 Fc region comprising substitutions at positions 298, 333 and 334 thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

21. (Currently Amended) The method of claim 19 wherein the variant comprises a variant human IgG1 Fc region comprising one or more amino acid substitutions at positions 256, 290, 298, 312, 326, 330, 333, 334, 360, 378, or 430 thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

22. (New) A method for treating lymphoma in a mammal comprising administering to the mammal a therapeutically effective amount of a variant of a parent antibody which binds CD20 and comprises a human IgG1 Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively than the parent antibody and comprises two or more amino acid substitutions in the Fc region, wherein the Fc region of the variant is not a native sequence Fc region.

23. (New) A method for treating lymphoma in a mammal comprising administering to the mammal a therapeutically effective amount of an anti-CD20 antibody which comprises a variant human IgG1 Fc region, which anti-CD20 antibody comprises two or more amino acid substitutions at positions 256, 290, 298, 312, 326, 330, 333, 334, 360, 378, or 430 of the Fc region thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

24. (New) A method for treating lymphoma in a mammal comprising administering to the mammal a therapeutically effective amount of an anti-CD20 antibody which comprises a variant human IgG1 Fc region, which variant comprises substitutions at positions 298, 333 and 334 of the Fc region thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.